Biologics Offer Targeted Efficacy in Psoriasis Management

Psoriasis is driven by dysregulation of the immune system, primarily involving T helper 1 (Th1), Th17, and Th22 pathways.¹ This understanding has been foundational in the development of biologic therapies, which are designed to selectively inhibit specific cytokines or cell surface receptors.² Prior to biologics, treatment options for moderate to severe psoriasis included phototherapy, methotrexate, cyclosporine, and acitretin. While effective for some, these agents are associated with systemic toxicities, requiring careful monitoring of hepatic, renal, and haematological parameters.³ Psoriasis affects approximately 2-3% of the global population, with varying prevalence across different ethnic groups. The disease manifests as chronic inflammation of the skin, characterized by erythematous plaques with silvery scales, often accompanied by pruritus. Beyond the visible skin manifestations, psoriasis is a systemic inflammatory disease associated with several comorbidities, including psoriatic arthritis, cardiovascular disease, metabolic syndrome, and depression. The significant impact on quality of life underscores the need for effective and well-tolerated treatment strategies. Traditional systemic therapies, while offering some relief, often present a challenging risk-benefit profile for long-term management due to their broad immunosuppressive effects and potential for organ toxicity.

Mechanisms of Action and Clinical Efficacy

Biologic agents for psoriasis primarily target tumour necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), or interleukin-23 (IL-23).⁴ TNF-α inhibitors, such as adalimumab, etanercept, infliximab, and certolizumab pegol, were among the first biologics approved for psoriasis.⁵ Clinical trials have consistently shown that these agents achieve significant reductions in disease severity. For instance, in a pooled analysis of two pivotal trials, adalimumab demonstrated a PASI 75 response rate of 71% at week 16.⁶ These trials typically involved adult patients with moderate to severe chronic plaque psoriasis, defined by a Psoriasis Area and Severity Index (PASI) score of at least 12, a Body Surface Area (BSA) involvement of at least 10%, and a Physician's Global Assessment (PGA) score of at least 3. Patients were often randomized to receive the biologic agent, placebo, or an active comparator, with efficacy assessed using standardized metrics like PASI 75, PASI 90, and PASI 100 response rates, which represent 75%, 90%, and 100% improvement from baseline PASI, respectively.

Subsequent developments led to the introduction of IL-17 inhibitors (e.g., secukinumab, ixekizumab, brodalumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab, risankizumab, tildrakizumab).⁷ These classes often exhibit even higher efficacy rates. For example, secukinumab achieved PASI 90 response rates of 79.0% and 76.4% at week 16 in two phase 3 trials, ERASURE and FIXTURE, respectively.⁸ Ixekizumab has shown PASI 90 response rates exceeding 70% by week 12 in multiple studies.⁹ IL-23 inhibitors, designed for less frequent dosing, have also demonstrated superior efficacy compared to TNF-α inhibitors in head-to-head trials. Guselkumab, for instance, achieved a PASI 90 response rate of 73.3% at week 16, compared to 49.7% for adalimumab, in the VOYAGE 1 study (p < 0.001).¹⁰ The targeted nature of these newer biologics allows for more precise interruption of specific inflammatory pathways implicated in psoriasis pathogenesis, potentially leading to improved efficacy and a more favorable safety profile compared to broader immunosuppressants. The IL-23 pathway, in particular, is upstream of the IL-17 pathway, and its inhibition can lead to a sustained reduction in IL-17 production, contributing to the observed long-term efficacy and less frequent dosing schedules.

The safety profiles of biologics are generally favourable, though they carry risks of infection, particularly upper respiratory tract infections, and potential for injection site reactions.¹¹ Specific risks vary by class; TNF-α inhibitors are associated with a slightly increased risk of tuberculosis reactivation, while IL-17 inhibitors may be linked to candidiasis.¹² Long-term data continue to accrue, supporting the sustained efficacy and acceptable safety of these agents over several years.¹³ Patients receiving biologics undergo regular monitoring for adverse events, including screening for latent tuberculosis before initiating TNF-α inhibitors. The overall benefit-risk assessment for biologics in moderate to severe psoriasis generally favors their use, especially in patients who have failed or are intolerant to conventional systemic therapies.

Despite their benefits, biologics are not universally effective, and a proportion of patients may experience primary or secondary treatment failure.¹⁴ Factors influencing response include disease severity, previous treatment history, and genetic predispositions.¹⁵ The high cost of biologic therapies also remains a significant consideration, impacting access and healthcare resource allocation.¹⁶ Furthermore, the long-term implications of sustained immune modulation, particularly regarding malignancy risk, require ongoing surveillance and research. While current data do not indicate a significant increase in overall malignancy risk with most biologics, specific concerns, such as non-melanoma skin cancer, warrant continued monitoring. The development of biosimilars offers a potential avenue to address the cost barrier, increasing patient access to these effective treatments. However, challenges remain in ensuring interchangeability and patient confidence in biosimilar products. Future research focuses on identifying biomarkers to predict treatment response, optimizing treatment sequencing, and developing novel therapies for non-responders.